These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3342412

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 24. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.
    Anticancer Res; 2003 May; 23(6D):5037-42. PubMed ID: 14981964
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y.
    Cancer Res; 1983 Jul 01; 43(7):3412-6. PubMed ID: 6850647
    [Abstract] [Full Text] [Related]

  • 27. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA, Beardsley GP, Krikorian JG, Mortara RW, Agarwal RP.
    Cancer Res; 1983 Nov 01; 43(11):5190-3. PubMed ID: 6616454
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
    Harris AL.
    Cancer Res; 1981 Jul 01; 41(7):2977-9. PubMed ID: 6941850
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 01; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C.
    Liversidge GG, Nishihata T, Engle KK, Higuchi T.
    J Pharm Pharmacol; 1986 Mar 01; 38(3):223-4. PubMed ID: 2871161
    [Abstract] [Full Text] [Related]

  • 38. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 01; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ, Gaudio L, Yesair DW, Schoenemann PT, Wodinsky I.
    Cancer Treat Rep; 1978 Jul 01; 62(7):1025-32. PubMed ID: 80268
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.